1790-91-6

Usage

Uses

Used in Medicinal Chemistry:
2,3-Dichloro-6,7-dimethoxyquinoxaline is used as a key intermediate in the synthesis of various pharmaceutical compounds for its potential therapeutic applications. 2,3-DICHLORO-6,7-DIMETHOXYQUINOXALINE's structural features, including the presence of halogens and methoxy groups, contribute to its biological activity, making it a promising candidate for drug development.
Used in Research and Development:
In the scientific community, 2,3-Dichloro-6,7-dimethoxyquinoxaline is utilized as a research tool to study the effects of its structural components on biological systems. This helps in understanding the compound's interactions with biological targets and its potential applications in the development of new therapeutic agents.
Used in Drug Design and Optimization:
2,3-Dichloro-6,7-dimethoxyquinoxaline serves as a building block in the design and optimization of new drugs. Its unique structural features allow for the creation of novel chemical entities with improved pharmacological properties, such as increased potency, selectivity, and reduced side effects.
Used in Chemical Synthesis:
2,3-DICHLORO-6,7-DIMETHOXYQUINOXALINE is also used as a reagent in various chemical synthesis processes, where its versatile structure can be further modified to produce a range of different chemical products with potential applications in various industries, including pharmaceuticals, materials science, and agrochemicals.

InChI:InChI=1/C10H8Cl2N2O2/c1-15-7-3-5-6(4-8(7)16-2)14-10(12)9(11)13-5/h3-4H,1-2H3

Upstream product

• 4784-02-5 6,7-dimethoxy-1,4-dihydro-quinoxaline-2,3-dione 

Relevant academic research and scientific papers

Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient

Provided are a novel [1,2,4]triazolo[4,3-a]quinoxaline derivative, a method for preparing the same, and a pharmaceutical composition for preventing or treating bromodomain extra-terminal (BET) protein-related diseases including cancer and autoimmune disea

Novel [1,2,4]triazolo[4,3-a]quinoxaline amino phenyl derivatives or pharmaceutically acceptable salts thereof, preparation method therof and pharmaceutical composition for use in preventing or treating bromodomain extra-terminal(BET) protein activity related diseases containing the same as an active ingredient

The present invention refers to [1, 2, 4] triazolo [4, 3 a-a] the [khwi [khwi] roh it was cut aminophenyl derivatives or pharmaceutically acceptable salts, including BET and manufacturing method of active ingredient (bromodomain extra non-terminal) a pharmaceutical composition for preventing or treating protein related disorders are disclosed. The present invention according to [1, 2, 4] triazolo [4, 3 a-a] aminophenyl derivatives of one of the [khwi [khwi] roh it was cut low concentrations in the BET protein family protein and an excellent BRD4 billion number, so that the inducing cytotoxicity against tumor cell lines, BET diseases associated with protein, in particular can be useful in preventing or treating cancer or an autoimmune disease. (by machine translation)

Imidazoquinoxaline protein tyrosine kinase inhibitors

Novel imidazoquinoxalines and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic disorders.